Colin Walsh

Dr. Colin Walsh is a Partner at Qiming Venture Partners USA and is based in South San Francisco, CA. He currently serves on the boards of Elevation Oncology, Korro Bio, and Element Science and is a board observer of Amphivena Therapeutics, Icosavax, and Ventyx Biosciences. He further serves on the business advisory board for the Harvard Medical School Initiative for RNA Medicine and is an advisor to the Stanford SPARK program and the UCSF Catalyst program, where he provides mentorship and support to students- and faculty-led translational research projects. Before joining Qiming, Dr. Walsh was a Vice President on the life science investment team at ND Capital where he sourced, structured, and managed investments in biotech, biopharma, and platform companies. Prior to ND Capital, he held a number of roles as an early employee at Precision NanoSystems, a 5 AM Ventures-backed biotech developing a suite of technologies to enable the development of RNA-based therapeutics and other complex drug formulations. Dr. Walsh earned a Ph.D. from the UC Berkeley – UCSF Graduate Program in Bioengineering, where he worked on novel delivery systems for RNA therapeutics as an NSF Graduate Research Fellow.